Connect Biopharma Holdings Ltd. has announced a significant milestone in its regulatory efforts, with the submission of a new drug application for rademikibart for the treatment of atopic dermatitis $(AD)$ to China's National Medical Products Administration (NMPA). This submission was made by Simcere, Connect Biopharma's exclusive licensee in Greater China. The application marks an important step in bringing rademikibart, a promising treatment with demonstrated efficacy and safety for eosinophilic-driven type 2 asthma and COPD, closer to market availability in the region. As the review process progresses, Connect Biopharma continues to advance its clinical programs, including ongoing Phase 2 studies for asthma and COPD.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001835268-25-000051), on August 13, 2025, and is solely responsible for the information contained therein.